The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
The effect of brexpiprazole (OPC-34712) and aripiprazole in adult patients with acute schizophrenia: results from a randomized, exploratory study
Open accessAbstract
The aim of this study was to explore the effects of brexpiprazole and aripiprazole on efficacy, cognitive functioning, and safety in patients with acute schizophrenia. Patients who would benefit from hospitalization/continued hospitalization for acute relapse of schizophrenia were enrolled and randomized (2 : 1) to target doses of open-label brexpiprazole 3 mg/day or aripiprazole 15 mg/day for 6 weeks. Outcomes included change from baseline to week 6 in the Positive and Negative Syndrome Scale total score, Barratt Impulsiveness Scale 11-item score, and Cogstate computerized cognitive test battery scores. Patients treated with brexpiprazole (n=64) or aripiprazole (n=33) showed reductions in symptoms of schizophrenia as assessed by Positive and Negative Syndrome Scale total score (-22.9 and -19.4, respectively). A modest reduction in impulsivity was observed with brexpiprazole, but not aripiprazole (mean change in the Barratt Impulsiveness Scale 11-item total score: -2.7 and 0.1, respectively). No change in Cogstate scores was observed for either treatment. Brexpiprazole was well tolerated and the incidence of akathisia was lower in patients treated with brexpiprazole (9.4%) than aripiprazole (21.2%). Clinically relevant improvements in psychopathology were observed in patients with acute schizophrenia treated with brexpiprazole or aripiprazole. Brexpiprazole was well tolerated, with a lower incidence of akathisia than aripiprazole.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In brief, results from this trial demonstrated comparable efficacy, as measured by similar reductions in PANSS scores from baseline to week 6, similar rates of weight gain, but lower rates of akathisia in the brexpiprazole group (9.4%) vs the aripiprazole group (21.2%).”
From Brexpiprazole for the maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy (2019) · cites this paper as [18]
In the citing paper
“At this time, there has been one open-label trial comparing brexpiprazole 3 mg daily to aripiprazole 15 mg daily for the acute (6-week) treatment of schizophrenia.18”
From Brexpiprazole for the maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy (2019) · cites this paper as [18]
Citations
Cites
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
(1998) · The Journal of Clinical Psychiatry · Cited by 19,139
Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111704 · Cited by 5,157 · cited 3×
“Safety and tolerability assessments included AEs; the following EPS scales: Simpson Angus Scale (Simpson and Angus, 1970), Abnormal Involuntary Movement Scale (Guy, 1976), and the Barnes Akathisia Rating Scale (BARS) (Barnes, 1989); body weight; laboratory tests; vital signs; Columbia Suicide Severity Rating Scale (Po…”
MethodA RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
Simpson, G. M., B., M., B., G., Angus, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,265
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561 · cited 4×
“…the variability in accompanying side effects (Correll, 2010), including weight gain, sedation, restlessness/agitation, akathisia, QTc prolongation, extrapyramidal symptoms (EPSs), and hyperprolactinemia (and associated sexual effects) (Kane et al., 2010; De Hert et al., 2012b; Leucht et al., 2013).”
BackgroundInfluentialThe MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity
Nuechterlein, K. H., Green, M. F., Kern, R. S., Baade, L. E., Barch, D. M., Cohen, J. D., Essock, S., Fenton, W. S., Frese, F. J., Gold, J. M., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07010042 · Cited by 2,342
A Rating Scale for Drug-Induced Akathisia
Barnes, T. R. E. (1989) · The British Journal of Psychiatry · doi:10.1192/bjp.154.5.672 · Cited by 2,179
A Systematic Review of the Prevalence of Schizophrenia
Saha, S., Chant, D., Welham, J., & McGrath, J. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020141 · Cited by 2,168
Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.
De Hert, M., Detraux, J., van Winkel, R., Yu, W., & Correll, C. U. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.156 · Cited by 1,145
Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology
Shapiro, D. A., Renock, S. M., Arrington, E. G., Chiodo, L. A., Liu, L.-X., Sibley, D. R., Roth, B. L., & Mailman, R. B. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300203 · Cited by 982
Research works printed but not linked: 3
- Celada, 2004, J Psychiatry Neurosci, 29, 252
- Levi, 2013, Curr Psychiatry, 12, 38
- Sheehan, 1998, J Clin Psychiatry, 59, 22
Cited by
Sorted by citations
Solmi, M., Murru, A., Pacchiarotti, I., Undurraga, J., Veronese, N., Fornaro, M., Stubbs, B., Monaco, F., Vieta, E., Seeman, M., et al. (2017) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s117321 · Cited by 438
Polypharmacology: The science of multi-targeting molecules
Kabir, A., & Muth, A. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2021.106055 · Cited by 245
Ward, K., & Citrome, L. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s169369 · Cited by 181
“Brexpiprazole vs aripiprazole At this time, there has been one open-label trial comparing brexpiprazole 3 mg daily to aripiprazole 15 mg daily for the acute (6-week) treatment of schizophrenia.(18) Participants were enrolled in this study if they were having an acute relapse of schizophrenia, and were then randomized…”
Self-citationLobo, M. C., Whitehurst, T., Kaar, S. J., & Howes, O. D. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.11.032 · Cited by 97
Comparative Tolerability of Dopamine D2/3 Receptor Partial Agonists for Schizophrenia
Keks, N. A., Hope, J., Schwartz, D., McLennan, H., Copolov, D., & Meadows, G. N. (2020) · CNS Drugs · doi:10.1007/s40263-020-00718-4 · Cited by 74
Metadata
- Authors
- Citrome, L., Ota, A., Nagamizu, K., Perry, P., Weiller, E., & Baker, R. A.
- Affiliations
- New York Medical College (US)
- Creative Commons (US)
- Corresponding author
- Citrome, Leslie
- Venue
- International Clinical Psychopharmacology
- Published
- 2016-07
- Volume
- 31
- Issue
- 4
- Pages
- 192-201
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W2295051011
- Cited by
- 74
- References
- 41
- Citations by year
- 2026: 6 · 2025: 9 · 2024: 6 · 2023: 4 · 2022: 6 · 2021: 6 · 2020: 11 · 2019: 8 · 2018: 2 · 2017: 7 · 2016: 6
- FWCI
- 6.82
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- International Clinical Psychopharmacology (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- brexpiprazole, aripiprazole, acute schizophrenia, schizophrenia relapse, akathisia, impulsivity, cognitive function, antipsychotic efficacy, drug safety, hospitalization
- MeSH terms
- Aripiprazole, Acute Disease, Adult, Dose-Response Relationship, Drug, Female, Humans, Male, Middle Aged, Schizophrenia, Thiophenes, Antipsychotic Agents, Quinolones, Weight Gain, Treatment Outcome, Akathisia, Drug-Induced, Serotonin Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
